Philippe Calais - 19 May 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Director
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
19 May 2023
Net transactions value
$0
Form type
4
Filing time
19 May 2023, 20:06:16 UTC
Previous filing
10 May 2023
Next filing
18 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAZ Stock Option (right to buy) Award $0 +45,000 $0.000000 45,000 19 May 2023 Common Stock 45,000 $0.2834 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time.